A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
Clinical trial NCT06382142 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06382142
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-21
- Primary completion
- 2026-01-13
- Enrollment
- 418
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.